Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation

摘要

Objective Recent data have suggested that nonselective beta-blockers (NSBB) are associated with increased mortality in patients with cirrhosis and refractory ascites. However, other evidence implies that NSBB may be beneficial in this setting by reducing bacterial translocation. Our aim was to determine whether NSBB use was a risk factor for mortality in patients with end-stage chronic liver disease and ascites awaiting liver transplantation.